RXRX Q2 2021 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M

Gross Profit

$3M100.0% margin

Operating Income

-$41M-1637.2% margin

Net Income

-$43M-1736.0% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$40M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$699M

Total Liabilities

$56M

Stockholders' Equity

$643M

Cash & Equivalents

$633M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$0	—
Gross Profit	$3M	$0	—
Operating Income	-$41M	-$18M	-124.7%
Net Income	-$43M	-$19M	-129.1%

Revenue Segments

License and Service

$3M98%

Grant

$49,0002%